[Targeting insulin-like growth factors in the treatment of cancer].
BACKGROUND
The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer growth, tumor cell survival and resistance to therapy.


BACKGROUND
Preclinical evidence that targeting the IGF-IR is effective in cancer treatment has been accumulating for almost 2 decades. Early clinical trials revealed an acceptable safety profile together with pharmacodynamic evidence that the receptor can be targeted successfully. It is premature to draw conclusions regarding the therapeutic potential of this class of compounds but well-documented single-agent activity was noted during phase I evaluations, and recent evidence from a phase-II study suggests that co-administration of an anti-IGF-1R antibody with chemotherapy for non-small-cell lung cancer (NSCLC) improves objective response rate and progression-free survival.


RESULTS
These early results are a strong indication for continued research on the targeting of IGF-R, particularly in the treatment of NSCLC.


CONCLUSIONS
Today, IGF-1R targeting appears a promising approach, more than two dozen compounds have been developed and clinical trials are underway.
Moro-Sibilot
D
D
UF oncologie thoracique, pole de médecine aiguë communautaire, CHU Albert-Michallon, BP 217, 38043 Grenoble cedex 9, France. DMoro.pneumo@chu-grenoble.fr
Coudurier
M
M
Lantuejoul
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007167:Immunotherapy; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins / Q000502:physiology; D007334:Insulin-Like Growth Factor I / Q000502:physiology*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D009363:Neoplasm Proteins; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1